R1 RCM Inc (NASDAQ:RCM) has earned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokerages have set a 12-month consensus price target of $5.00 for the company and are predicting that the company will post $0.02 earnings per share for the current quarter, according to Zacks. Zacks has also given R1 RCM an industry rank of 93 out of 265 based on the ratings given to its competitors.
A number of research analysts have issued reports on the stock. BidaskClub raised shares of R1 RCM from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Zacks Investment Research cut shares of R1 RCM from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th.
Shares of R1 RCM (NASDAQ:RCM) opened at $4.68 on Tuesday. The company has a market cap of $509.25, a PE ratio of -18.00 and a beta of -0.41. R1 RCM has a 12-month low of $2.02 and a 12-month high of $5.43.
TRADEMARK VIOLATION WARNING: “Brokerages Expect R1 RCM Inc (RCM) to Announce $0.02 Earnings Per Share” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/13/brokerages-expect-r1-rcm-inc-rcm-to-announce-0-02-earnings-per-share.html.
R1 RCM Company Profile
R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.